BioNTech plans to price its COVID-19 vaccine below market rates

BioNTech, which is first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below typical market rates.
It is also planning to differentiate pricing between countries or regions.
Speaking Tuesday at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer, would reflect the financial risks that its private-sector investors have incurred.
The vaccine has yet to get regulatory approval.
The vaccine on Monday showed to be 90% effective, based on preliminary trial results.
The development is a key milestone in the war against a virus that has killed more than a million people and battered the world's economy.

comments powered by Disqus
More Stories
Most Popular
MAJ calls for use of Ivermectin to help treat...
Boeing recommends grounding 777 models after...
Landslide victory for TCI opposition party